Abstract: A charging apparatus, a charging pile, and a charging system. The charging apparatus includes a positive bus, a negative bus, a DC/DC conversion circuit, and a soft-start circuit. The soft-start circuit is connected to an input end of the DC/DC conversion circuit through the positive bus and the negative bus, and the input end of the DC/DC conversion circuit is connected to a photovoltaic apparatus or an energy storage apparatus through the positive bus and the negative bus. Therefore, when a first voltage between the positive bus and the negative bus is greater than or equal to a first threshold, the DC/DC conversion circuit may perform power conversion on a second voltage received from the photovoltaic apparatus or the energy storage apparatus, and output the second voltage obtained after power conversion.

Abstract: The present invention provides an anti-PD-L1/anti-CD47 bispecific antibody and a preparation method therefor. The antibody has characteristics of a natural IgG, and is a highly stable heterodimeric form without heavy and light chain mismatching. The bispecific antibody can bind two target molecules at the same time and has a smaller side effect.

Abstract: Provided are an anti-PD-L1/anti-4-1BB natural antibody structure-like heterodimeric form bispecific antibody and a preparation thereof. Specifically, provided are an anti-PD-L1/anti-4-1BB bispecific antibody that has natural IgG features, that has no mismatch between heavy and light chains and that is in the form of a highly stable heterodimer, as well as a preparation method therefor. The bispecific antibody can simultaneously bind two target molecules and is more effective in treating complex diseases and has fewer side effects.

Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.

Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.

Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.

Abstract: The present disclosure provides a method of separating hematopoietic stem cells from umbilical cord blood, including the following steps: a hydroxyethyl starch solution is added into cord blood and mixed uniformly, then centrifuged to get an upper liquid layer and a lower erythrocyte layer; the liquid in the upper layer and the erythrocytes in the lower layer are centrifuged respectively; an upper plasma layer and a basal cell layer are obtained after the centrifugation of the upper liquid layer, the cells in the basal layer are resuspended; a superficial buffy-coat layer is obtained after the centrifugation of the erythrocytes, and the superficial buffy-coat layer is metered with the plasma in the upper layer, and then centrifuged to get a lower cell layer, which is precipitated to remove erythrocytes and then resuspended; the above resuspended cells are added into freezing medium, mixed uniformly and then stored in a liquid nitrogen tank.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.

Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.

Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.

Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.

Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.

Abstract: A guard assembly for an abrasive accessory of a power tool is provided, including a guard shell being associated with a first surface of the abrasive accessory and secured to the power tool around an output spindle of the power tool; and a guard cover being associated with a second surface of the abrasive accessory opposite the first surface and attached to the guard shell at a pivot point having an axis that is at a distance from an axis of the spindle, the guard cover being rotatably movable with respect to the guard shell around the pivot point.

Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.

Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.